Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

InductionChemo-Radio-Antibody-Treatment (ICRAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01181401
Recruitment Status : Completed
First Posted : August 13, 2010
Last Update Posted : January 31, 2019
Sponsor:
Information provided by (Responsible Party):
Carmen Stromberger, Charite University, Berlin, Germany

Brief Summary:

This is an open-label, randomized, Phase II-study to evaluate the efficacy of a standard-TPF induction chemotherapy (IC) and an alternative TPF induction chemotherapy followed by radio-antibody-therapy, in patients with unresectable LA-SCC of the HN region (oro-hypopharynx carcinoma, cancer of the oral cavity).

The primary objective of the study is to assess the feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.

Composite endpoint of compliance and feasibility in terms of

  • response (RECIST1.1) and
  • hematological acute toxicity (CTCAE v.4.02)
  • on time application of RAT following an experimental or standard TPF IC.

Secondary endpoints are

  • Treatment intensity achieved
  • Toxicity (according to CTCAE v.4.02)
  • Response rates after completion of induction chemotherapy and after completion of entire protocol treatment (RECIST1.1)
  • Survival (progression-free, metastasis-free, recurrence-free, overall) 1 year after randomisation
  • Quality of life according to EORTC QoL C30 & HN35

The study will be conducted at 5-6 investigational sites in Germany recruiting 90 patients in total. Eligible patients will have a diagnosis of histologically confirmed SSC of the HN. Patients will receive one of 2 different regimens of TPF IC followed by cetuximab together with radiotherapy (RAT) or a standard radiochemotherapy(RCT) regimen.


Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Head Squamous Cell Carcinoma of the Neck Drug: TPF induction chemotherapy Drug: TPF experimental Radiation: Standard Radiochemotherapy (HART) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck
Study Start Date : August 2010
Actual Primary Completion Date : April 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab

Arm Intervention/treatment
Active Comparator: TPF standard

TPF version 1 (standard)

  1. Induction chemotherapy:

    Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles

  2. Antibody therapy with:

    cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX

  3. RTX: HART (72 Gy), IMRT or 3D-conformal techniques
Drug: TPF induction chemotherapy
Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Other Names:
  • Docetaxel (Taxotere)
  • Cisplatin
  • 5-Flurouracil
  • Cetuximab (Erbitux)

Experimental: TPF experimental

TPF version 2 (experimental)

  1. Induction chemotherapy:

    Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles

  2. Antibody therapy with:

    cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX

  3. RTX: HART (72 Gy), IMRT or 3D-conformal techniques
Drug: TPF experimental
Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Other Names:
  • Docetaxel (Taxotere)
  • Cisplatin
  • 5-Flurouracil
  • Certuximab

Active Comparator: Standard RCT

Standard RCT:

  1. HART (72 Gy), IMRT or 3D-conformal techniques
  2. with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5
Radiation: Standard Radiochemotherapy (HART)
Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
Other Names:
  • Cis-platinum
  • 5-FU




Primary Outcome Measures :
  1. Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen. [ Time Frame: August 2010- December 2012 ]
    acute hematological toxicity


Secondary Outcome Measures :
  1. Survival and late morbidity [ Time Frame: 1 year ]
    All adequate items illustrating acute toxicity and late morbidity, in particular by hematological measures until one year after treatment (according to NCI-CTCAE v.4.02) Survival (progression-free, metastases-free, recurrence-free, Overall survival) after 1 year Response rates after TPF IC (RECIST1.1) Response rates after completion of multimodal treatment (see follow-up for scheduling RECIST1.1) Efficacy in relation to HPV status (p16 IHC) Quality of life according to EORTC QLC-30 & HN35



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven unresectable SCC of the oral cavity, oropharynx and hypopharynx (stage IVA & IVB)
  • Written and signed informed consent
  • Karnofsky PS > 70 %
  • Age ≥ 18 years
  • Curative treatment intent
  • Adequate bone marrow, hepatic and renal functions as evidenced by the following:

Hematology (Bone marrow):

  • Neutrophils > 2.0 109/L
  • Platelets > 100 x 109/L
  • Hemoglobin > 10 g/dL

Hepatic function:

  • Total serum bilirubin < 1 time the UNL of the participating center
  • ASAT (SGOT) and ALAT (SGPT) < 2.5 x UNL
  • Alkaline phosphatase < 5 x UNL

Renal function :

  • serum creatinine (SC) < 120 µmol/L (1.4 mg/dl);
  • if values are > 120 µmol/L, the creatinine clearance should be > 60 ml/min (actual or calculated by the Cockcroft-Gault method as follows :

weight (kg) x (140 - age) --------------------------------- K x serum creatinine

serum creatinine in mg/dL: K = 72 in man K = 85 in woman serum creatinine in µmol/L: K = 0.814 in man K = 0.96 in woman

• If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing.

All patients require:

  • dental examination and appropriate dental preservation if needed 1 week prior to the beginning of radiotherapy,
  • gastric feeding tube and Portal-catheter.

Exclusion Criteria:

  • Other neoplasia within the past 5 years with the exception of a controlled skin cancer or "in situ" cervix cancer
  • Unknown primary (CUP), nasopharynx, laryngeal or salivary gland cancer
  • Distant metastatic disease (M1)
  • Serious co-morbidity, e.g. arteriosclerosis with apoplexy, recent myocardial infarction, high-grade carotid stenoses, unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4, insulin-dependent diabetes mellitus, uncontrolled hypertension, liver cirrhosis (Quick < 75%, total protein <3.0 g/dl, bilirubin >2mg/ml) or kidney insufficiency (creatinine >1.4 mg/ml, the creatinine clearance should be > 60 ml/min)
  • patients with ASAT or ALAT > 2.5 UNL associated with alkaline phosphatase > 5 UNL are not eligible for the study
  • Known HIV-infection
  • Pregnancy or lactation
  • Women of child-bearing potential with unclear contraception
  • Previous treatment of the disease with chemotherapy, radiotherapy, EGFR-targeting agents or surgery exceeding biopsy in head and neck
  • Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening
  • Social situations that limit compliance with study requirements
  • Deficient dental preservation status or not accomplished wound healing
  • Legal incapacity
  • Prior accommodation in an institution under officially or judicially orders (§ 40 1 p. 3 No. 4 AMG)
  • Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 and/or ototoxicity grade 2, except if due to trauma or mechanical impairment due to tumor mass
  • Known allergic/hypersensitivity reaction to any of the components of the treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181401


Locations
Layout table for location information
Germany
Charité Universitaetsmedizin Berlin, CVK, CBF
Berlin, Germany, 13353
University Medical Center Hamburg - Eppendorf
Hamburg, Germany, 20246
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Universitätsklinikum Gießen und Marburg
Marburg, Germany, 35043
Universitätsklinikum Regensburg
Regensburg, Germany, 93053
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Layout table for investigator information
Principal Investigator: Volker Budach, MD, PhD Charité Universitaetsmedizin Berlin
Publications of Results:

Layout table for additonal information
Responsible Party: Carmen Stromberger, Prof. Dr. Volker Budach, Charite University, Berlin, Germany
ClinicalTrials.gov Identifier: NCT01181401    
Other Study ID Numbers: EudraCT No. 2010-019347-18
First Posted: August 13, 2010    Key Record Dates
Last Update Posted: January 31, 2019
Last Verified: January 2019
Keywords provided by Carmen Stromberger, Charite University, Berlin, Germany:
induction chemotherapy
radiotherapy
locally advanced head neck tumor
toxicity
LA SCCHN
Unresectable squamous cell cancer of the head and neck,
Stage IV (UICC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Cisplatin
Docetaxel
Cetuximab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological